3-(N-Arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2)
- 15 April 2012
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (8), 2789-2793
- https://doi.org/10.1016/j.bmcl.2012.02.089
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Structure-Based Design of Pseudopeptidic Inhibitors for SIRT1 and SIRT2Journal of Medicinal Chemistry, 2011
- Structure–Activity Studies on Suramin Analogues as Inhibitors of NAD+‐Dependent Histone Deacetylases (Sirtuins)ChemMedChem, 2007
- Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's DiseaseScience, 2007
- N,N‘-Bisbenzylidenebenzene-1,4-diamines andN,N‘-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) InhibitorsJournal of Medicinal Chemistry, 2006
- Adenosine Mimetics as Inhibitors of NAD+-Dependent Histone Deacetylases, from Kinase to Sirtuin InhibitionJournal of Medicinal Chemistry, 2006
- Insights into the Sirtuin Mechanism from Ternary Complexes Containing NAD+ and Acetylated PeptideStructure, 2006
- Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzleGenes & Development, 2006
- Mechanism of Sirtuin Inhibition by Nicotinamide: Altering the NAD+ Cosubstrate Specificity of a Sir2 EnzymeMolecular Cell, 2005
- A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivoProceedings of the National Academy of Sciences of the United States of America, 2005
- Structure of the histone deacetylase SIRT2.Nature Structural & Molecular Biology, 2001